Therapeutic targeting of extracellular FGFR2 activating deletions in intrahepatic cholangiocarcinoma.

567Background: Fibroblast growth factor receptor (FGFR) pathway alterations have been identified in approximately 20% of patients (pts) with intrahepatic cholangiocarcinoma (IHCC), most commonly by...